# An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B

> **NCT02213250** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **DRUG:** BENEFIX

## Key facts

- **NCT ID:** NCT02213250
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02213250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02213250, "An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02213250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*